Journal of Peking University(Health Sciences) ›› 2014, Vol. 46 ›› Issue (5): 686-690.

• Articles • Previous Articles     Next Articles

Evaluation and indication of human epithelial growth factor receptor 2 status in breast carcinoma with amplified chromosome 17 centromere locus

ZHANG Shuang1*, WANG Ying1*, GUO Zheng-min1, ZHANG Hong1, XU Ling2, LIU Yin-hua2, LI Ting1△   

  1. (1.Department of Pathology, 2. Breast Center, Peking University First Hospital, Beijing 100034, China)
  • Online:2014-10-18 Published:2014-10-18

Abstract: Objective: To study the evaluation of human epithelial growth factor receptor 2 (HER2) status in breast carcinoma with amplified chromosome 17 centromere locus (CEP17) and clinical significance of CEP17 amplification. Methods: Two hundred-eighteen cases of breast carcinoma were collected. We performed immunohistochemistry (IHC) to test HER2 protein and fluorescence in situ hybridization (FISH) to evaluate HER2 gene status. Results: Two cases in this cohort manifested CEP17 amplification. HER2 signals for case 1 was countable, and the average number was 2.6 per one nuclei, and the signals of CEP17 were clustered or multipunctiform. This case was evaluated as no HER2 amplification, but with amplified CEP17 . In case 2 the signals of HER2 and CEP17 were countable, and the average number of HER2 signal was 6.8 per one nucleus while CEP17 signal was 5.9 per one nucleus. The status was considered as HER2 and CEP17 coamplification. And the levels of HER2 protein expression of these two cases were both two plus. Conclusion: The incidence of CEP17 amplification in breast carcinoma is rare, with or without HER2 amplification. We recommend to evaluate the exact HER2 status by the HER2 copy number, and should also analyze the HER2/CEP17 ratio and the level of HER2 protein, for providing more accurate evidence to support the clinical target therapy.

Key words: Breast neoplasms, Gene, erbB-2, In situ hybridization, fluorescence, Centromere

[1] Yan-hong MENG,Yi-fan CHEN,Pei-ru ZHOU. Clinical and immunological features of primary Sjögren's syndrome patients with positive anti-centromere protein B antibody [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1088-1096.
[2] Jian-xun MA,You-chen XIA,Bi LI,Hong-mei ZHAO,Yu-tao LEI,Xi BU. Choice of immediate breast reconstructive methods after modified radical mastectomy [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 612-618.
[3] Yu-xiao WU,Yi-fan KANG,Qian-ying MAO,Zi-meng LI,Xiao-feng SHAN,Zhi-gang CAI. Application of methylene blue near-infrared fluorescence imaging for oral sentinel lymph node mapping in rats [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 684-688.
[4] Yun-jing ZHANG,Li-ying QIAO,Meng QI,Ying YAN,Wei-wei KANG,Guo-zhen LIU,Ming-yuan WANG,Yun-feng XI,Sheng-feng WANG. Development and validation of risk prediction model for new-onset cardiovascular diseases among breast cancer patients: Based on regional medical data of Inner Mongolia [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 471-479.
[5] Wei WANG,Xin LI,Ping LIU,Ying DONG. Clinical value of fluorescence in situ hybridization with MDM2 and DDIT3 probe in diagnosis of liposarcoma [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 228-233.
[6] Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862.
[7] CHI Yan-ting,ZHANG Yan-ping,ZHANG Qiu-lu,LIU Cui-ling,LI bin-bin. Clinicopathological analysis of mucosa associated lymphoid tissue lymphoma secondary to Sjögren’s syndrome in salivary gland [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 40-45.
[8] Shu-dong ZHANG,Peng HONG,Bin-shuai WANG,Shao-hui DENG,Fan ZHANG,Li-yuan TAO,Cai-guang CAO,Zhen-hua HU,Lu-lin MA. Usefulness of the indocyanine green fluorescence imaging technique in laparoscopic partial nephrectomy [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 657-662.
[9] Bing-wei HUANG,Jie WANG,Peng ZHANG,Zhe LI,Si-cheng BI,Qiang WANG,Cai-bo YUE,Kun-lin YANG,Xue-song LI,Li-qun ZHOU. Application of indocyanine green in complex upper urinary tract repair surgery [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 651-656.
[10] Guo-hong SONG,Hui-ping LI,Li-jun DI,Ying YAN,Han-fang JIANG,Ling XU,Dong-gui WAN,Ying LI,Mo-pei WANG,Yu XIAO,Ru-yan ZHANG,Ran RAN,Huan WANG. Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 254-260.
[11] Jia-yu WANG,Mei-ping ZHAO. Fluorescence assay for the detection of apurinic/apyrimidinic endonuclease 1 (APE1) activity in human blood samples [J]. Journal of Peking University(Health Sciences), 2019, 51(3): 487-492.
[12] KANG Lei, HUO Yan, WANG Rong-fu, ZHANG Chun-li, YAN Ping, XU Xiao-jie. In vivo imaging of breast tumors by a 99mTc radiolabeled probe targeting microRNA-155 in mice models [J]. Journal of Peking University(Health Sciences), 2018, 50(2): 326-330.
[13] ZHU Yan,SHI Yong-jin,ZHAO Yu-liang, ZHU Ping. Topoisomerase inhibitor upregulates MICA/B expression in breast cancer cells through ATM/ATR and NF-κB pathway [J]. Journal of Peking University(Health Sciences), 2018, 50(2): 318-325.
[14] FENG Yong-liang, FAN Jing-hui, LIN Xian-juan, YANG Ji-chun, CUI Qing-hua, TANG Xin-jing, XU Guo-heng, GENG Bin. Facilitating the measurement of circulatory hydrogen sulfide with fluorescence probe-coated microplates [J]. Journal of Peking University(Health Sciences), 2017, 49(6): 1060-1065.
[15] WANG Fang, ZHANG Yan-qin, DING Jie, YU Li-xia. Detection of large deletions in X linked Alport syndrome using competitive multiplex fluorescence polymerase chain reaction [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 760-767.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!